Friday, July 10, 2026

pharma · Systemic Lupus Erythematosus · Lupus Erythematosus, Systemic

Serana Europe

Serono Europe is a pharma organization headquartered in GB. Primary therapeutic focus areas include Systemic Lupus Erythematosus, Lupus Erythematosus, Systemic, First Line Non-Small Cell Lung Cancer, Coronavirus Disease

Pessin, DE HQ
2014 Founded
20 Employees
EMA registrant Type
Company details
Status
Public
HQ
Pessin, DE
Founded
2014
Employees
20
Programs
8
Drugs
8
Patents
0
Clinical program

Enpatoran low dose

Phase 2 · small molecule · Systemic Lupus Erythematosus

Enpatoran low dose for Systemic Lupus Erythematosus is a Phase 2 program (small_molecule) at Serono Europe Limited with 1 ClinicalTrials.gov record(s).

← All Serono Europe Limited projects Phase 2 small molecule completed

Internal code MS200569_0003

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Serono Europe Limited
Phase
Phase 2
Modality
small_molecule
Indication
Systemic Lupus Erythematosus
Status
completed
Trials
1